Skip to content
SPC Logo

Venofer (iron sucrose)

Last Updated on eMC 09-Nov-2016 View document  | Vifor Pharma UK Limited Contact details

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC.  For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 09-Nov-2016 and displayed until Current

Reasons for adding or updating:

  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.8 - Undesirable effects
  • Change to section 10 - Date of revision of the text

Date of revision of text on the SPC: 01-Sep-2016

Legal Category:POM

Black Triangle (CHM): YES

Free-text change information supplied by the pharmaceutical company:



4.2       Posology and method of administration

The patient should be observed for adverse effects for at least 30 minutes following each Venofer administration

4.4       Special warnings and precautions for use

Paravenous leakage must be avoided because leakage of Venofer at the injection site can lead to pain, inflammation and brown discoloration of the skin

4.8       Undesirable effects

Changes to the frequency and  terminology around certain adverse events

10                    Date of Revision of the Text

August 2016

Updated on 21-Jul-2016 and displayed until 09-Nov-2016

Reasons for adding or updating:

  • Change to section 8 - Marketing authorisation number(s)
  • Change to section 10 - Date of revision of the text

Date of revision of text on the SPC: 01-Jul-2016

Legal Category:POM

Black Triangle (CHM): YES

Free-text change information supplied by the pharmaceutical company:

$07. MARKETING AUTHORISATION HOLDER$0$0$0$0$0Has changed from$0$0$0$0$0Vifor France SA$0$07-13, Boulevard Paul-Emile Victor$0$092200 Neuilly-sur-Seine$0$0France$0$0Tel. +33 (0)1 41 06 58 90$0$0Fax +33 (0)1 41 06 58 99 $0$0$0$0$0To$0$0$0$0$0Vifor France $0$0100-101 Terrasse Boieldieu $0$0Tour Franklin La Défense 8$0$092042 Paris La Défense Cedex$0$0France$0$0Tel.  +33 (0)1 41 06 58 90$0$0Fax  +33 (0)1 41 06 58 99$0$0$0$0$010. DATE OF REVISION OF THE TEXT$0$0$0$0

Updated on 29-Feb-2016 and displayed until 21-Jul-2016

Reasons for adding or updating:

  • Change to section 4.6 - Fertility, pregnancy and lactation
  • Change to section 10 - Date of revision of the text

Date of revision of text on the SPC: 01-Feb-2016

Legal Category:POM

Black Triangle (CHM): YES

Free-text change information supplied by the pharmaceutical company:



The following addition has been made to: 4.6. Fertility, pregnancy and lactation

Fertility

No effects of iron sucrose treatment were observed on fertility and mating performance in rats.

10. DATE OF REVISION OF THE TEXT

07/201502/2016

Updated on 10-Nov-2015 and displayed until 29-Feb-2016

Reasons for adding or updating:

  • Change to section 4.1 - Therapeutic indications

Date of revision of text on the SPC: 01-Jul-2015

Legal Category:POM

Black Triangle (CHM): YES

Free-text change information supplied by the pharmaceutical company:



4.1.      Therapeutic indications


"In chronic kidney disease when oral iron preparations are less effective than Venofer"

Has now been amended to

"In chronic kidney disease when oral iron preparations are less effective"

Updated on 28-Sep-2015 and displayed until 10-Nov-2015

Reasons for adding or updating:

  • Change to section 4.1 - Therapeutic indications
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 5.2 - Pharmacokinetic properties
  • Change to section 10 - Date of revision of the text

Date of revision of text on the SPC: 01-Jul-2015

Legal Category:POM

Black Triangle (CHM): YES

Free-text change information supplied by the pharmaceutical company:

$04.1.      Therapeutic indications$0$0In chronic kidneydisease when oral iron preparations are less effective than Venofer.$0$0 $0$05.1.      Pharmacodynamic properties$0$0Additionof information on pharmacotherapeutic group: B03AC$0$0 $0$0Addition of information on Mechanism ofAction, and Clinical efficacy and safety$0$0 $0$05.2.      Pharmacokinetic properties$0$0Clarificationregarding Distribution, Biotransformation and Elimination $0

Updated on 01-Jul-2015 and displayed until 28-Sep-2015

Reasons for adding or updating:

  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.6 - Fertility, pregnancy and lactation
  • Change to section 4.7 - Effects on ability to drive and use machines
  • Change to section 4.8 - Undesirable effects
  • Change to section 4.9 - Overdose
  • Change to section 5.3 - Preclinical safety data
  • Change to section 6.1 - List of excipients
  • Change to section 6.2 - Incompatibilities
  • Change to section 6.3 - Shelf life
  • Change to section 6.4 - Special precautions for storage
  • Change to section 6.5 - Nature and contents of container
  • Change to section 6.6 - Special precautions for disposal and other handling
  • Change to section 10 - Date of revision of the text
  • Change to section 4.2 - Posology and method of administration
  • Change to section 2 - Qualitative and quantitative composition

Date of revision of text on the SPC: 01-Feb-2015

Legal Category:POM

Black Triangle (CHM): YES

Free-text change information supplied by the pharmaceutical company:



2.       Qualitative and Quantitative Composition

Typographical change: “For the full list of excipients, see section 6.1”

 

4.2.    Posology and method of administration

Typographical change in subtitle:

“Posology and method of administration”

 

Addition of :

Posology

The cumulative dose of Venofer must be calculated for each patient individually and must not be exceeded.

 

Typographical changes in Ganzoni formula and unit change from “l” to “dl”

 

Removal of “Example”

 

Addition of  “Method of administration”

 

“Intravenous drip infusion” information has been tabulated with the inclusion of permissible dilutions.

 

Typographical changes to instructions regarding injection into the dialysis machine

 

4.3. Contraindications

Typographical changes

 

4.4.    Special warnings and precautions for use

Removal of: Hypotensive episodes may occur if the injection is administered too rapidly. Allergic reactions, sometimes involving arthralgia, have been more commonly observed when the recommended dose is exceeded

 

Typographical changes

 

4.5.    Interactions with other medicinal products and other forms of interaction

Typographical changes to title

 

4.6.    Fertility, pregnancy and lactation

Inclusion of: Data (303 pregnancy outcomes) from the use of Venofer in pregnant women in the second and third trimester showed no safety concerns for the mother or newborn.

 

Inclusion of: In one clinical study, 10 healthy breast-feeding mothers with iron deficiency received 100 mg iron in the form of iron sucrose. Four days after treatment, the iron content of the breast milk had not increased and there was no difference from the control group (n=5). It cannot be excluded that newborns/infants may be exposed to iron derived from Venofer via the mother’s milk, therefore the risk/benefit should be assessed.

 

In lactating rats treated with 59Fe-labelled iron sucrose, low secretion of iron into the milk and transfer of iron into the offspring was observed. Non metabolised iron sucrose is unlikely to pass into the mother’s milk.

 

4.8.    Undesirable effects

 

Inclusion of: The most commonly reported adverse drug reaction in clinical trials with Venofer was dysgeusia, which occurred with a rate of 4.5 events per 100 subjects. The most important serious adverse drug reactions associated with Venofer are hypersensitivity reactions, which occurred with a rate of 0.25 events per 100 subjects in clinical trials.

 

Data in the table has been tabulated.

 

4.9.    Overdose

Typographical changes  and inclusion of: Overdose should be treated, as deemed necessary by the treating physician, with an iron chelating agent or according to standard medical practice.

 

5.3.    Preclinical safety data

Amendment to: Non-clinical data reveal no special hazard for humans based on conventional studies of repeated dose toxicity, genotoxicity and toxicity to reproduction and development.

 

6.1.    List of excipients

Typographical change in subtitle

 

Amendment to: Sodium hydroxide (for pH adjustment)

 

6.3.    Shelf life

Typographical change in subtitle

Amendment to: Shelf life after dilution with sterile 0.9% m/V sodium chloride (NaCl) solution

 

6.4.    Special precautions for storage

Addition of: Store in the original package.

For storage conditions after dilution or first opening of the medicinal product, see section 6.3.

 

6.5.    Nature and contents of container

Typographical change in subtitle

 

6.6.    Special precautions for disposal and other handling

Addition of : Venofer must not be mixed with other medicinal products except sterile 0.9% m/V sodium chloride solution for dilution. For instructions on dilution of the product before administration, see section 4.2.

 

Removal of: Discard any remaining contents after first use.

 

Addition of: Any unused medicinal product or waste material should be disposed of in accordance with local requirements

Updated on 13-Nov-2013 and displayed until 01-Jul-2015

Reasons for adding or updating:

  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.6 - Fertility, pregnancy and lactation
  • Change to section 4.8 - Undesirable effects - how to report a side effect
  • Change to section 10 - Date of revision of the text
  • Addition of black triangle

Date of revision of text on the SPC: 01-Sep-2013

Legal Category:POM

Black Triangle (CHM): YES

Free-text change information supplied by the pharmaceutical company:

Section 4.2

Details on monitoring monitoring patients have been included. The test dose is no longer required.

In section 4.3

 

“hypersensitivity to the active substance, to Venofer or any of its excipients listed in section 6.1.” has replaced “known hypersensitivity to Venofer or to any of its excipients”

 

“known serious hypersensitivity to other parenteral iron products.” Has been added

In section 4.4

 

The following text has been incorporated:

 

Parenterally administered iron preparations can cause hypersensitivity reactions including serious and potentially fatal anaphylactic/anaphylactoid reactions. Hypersensitivity reactions have also been reported after previously uneventful doses of parenteral iron complexes.

 

The risk is enhanced for patients with known allergies including drug allergies, including patients with a history of severe asthma, eczema or other atopic allergy.

There is also an increased risk of hypersensitivity reactions to parenteral iron complexes in patients with immune or inflammatory conditions (e.g. systemic lupus erythematosus, rheumatoid arthritis).

 

Venofer should only be administered when staff trained to evaluate and manage anaphylactic reactions are immediately available, in an environment where full resuscitation facilities can be assured. Each patient should be observed for adverse effects for at least 30 minutes following each Venofer injection. If hypersensitivity reactions or signs of intolerance occur during administration, the treatment must be stopped immediately. Facilities for cardio respiratory resuscitation and equipment for handling acute anaphylactic/anaphylactoid reactions should be available, including an injectable 1:1000 adrenaline solution. Additional treatment with antihistamines and/or corticosteroids should be given as appropriate.

In section 4.5

The information on pregnancy has been updated.

In section 4.8

Details on reporting adverse events have been updated.



Updated on 30-Mar-2011 and displayed until 13-Nov-2013

Reasons for adding or updating:

  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 4.2 - Posology and method of administration
  • Change to section 6. 5 - Nature and Contents of Container
  • Change to section 7 - Marketing Authorisation Holder
  • Change to section 10 date of revision of the text

Date of revision of text on the SPC: 01-Feb-2011

Legal Category:POM

Black Triangle (CHM): NO

Free-text change information supplied by the pharmaceutical company:



 

·  In section 2. (Qualitative and quantitative composition) the following wording has been added:
 

 Each 5 ml ampoule of Venofer contains 100 mg iron as iron sucrose (iron(III)-hydroxide sucrose complex).


·
  In section 4.2 (Posology and Method of Administration) a number of changes have been implemented:


·        
The following wording has been added:

 

The total amount of Venofer required in mg is determined from above calculation.

Alternatively, the total amount of Venofer required in ml is determined from the following formula or dosage table.

 

Total amount of Venofer required [ml] = 

 

Dosage table stating the total amount of

Venofer in ml

:



Body

Weight

Total amount of Venofer to be administered

Hb 60 g/l

Hb 75 g/l

Hb 90 g/l

Hb 105 g/l

30 kg

47.5 ml

42.5 ml

37.5 ml

32.5 ml

35 kg

62.5 ml

57.5 ml

50 ml

45 ml

40 kg

67.5 ml

60 ml

55 ml

47.5 ml

45 kg

75 ml

65 ml

57.5 ml

50 ml

50 kg

80 ml

70 ml

60 ml

52.5 ml

55 kg

85 ml

75 ml

65 ml

55 ml

60 kg

90 ml

80 ml

67.5 ml

57.5 ml

65 kg

95 ml

82.5 ml

72.5 ml

60 ml

70 kg

100 ml

87.5 ml

75 ml

62.5 ml

75 kg

105 ml

92.5 ml

80 ml

65 ml

80 kg

112.5 ml

97.5 ml

82.5 ml

67.5 ml

85 kg

117.5 ml

102.5 ml

85 ml

70 ml

90 kg

122.5 ml

107.5 ml

90 ml

72.5 ml

 

 

Example: For a patient of 60 kg body weight with an actual Hb of 60 g/l 90 ml should be administered. (Alternatively 18 ampoules/vials of 5 ml or 36 vials of 2.5 ml should be administered.)

 

Under subheading intravenous drip infusion the following bullet point has been added:

 

·         2.5 ml Venofer (50 mg iron)
in max. 50 ml sterile 0.9% m/V sodium chloride solution

 

In addition under the subheading Intravenous injection the following wording has been amended from:


Intravenous injection: Venofer may be administered by slow intravenous injection at a rate of 1 ml undiluted solution per minute (i.e. 5 minutes per ampoule) and not exceeding 2 ampoules Venofer (200mg iron) per injection.’


To now read:

Intravenous injection: Venofer may be administered by slow intravenous injection at a rate of 1 ml undiluted solution per minute and not exceeding 10 ml Venofer (200 mg iron) per injection.

 

·  In section 6.5 (Nature and Contents of Container) the following wording has been added:

 

        2.5 ml solution in one vial (type I glass) in pack sizes of 5.

 

        Not all pack-sizes may be marketed

 

·  In section 7 (Marketing Authorisation Holder) the email address has been removed.


·
  In section 10 (Date of Revision of The Text) has been changed from 01.12.2008 to 02/2011.

Please note that minor formatting amendments have been made in section 4.3 (Contraindications), 4.4 (Special Warnings and Precautions for Use), 4.6 (Pregnancy and Lactation) and 4.8 (Undesirable Effects).

 

Updated on 27-Jan-2011 and displayed until 30-Mar-2011

Reasons for adding or updating:

  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.8 - Undesirable Effects
  • Change to section 6. 5 - Nature and Contents of Container
  • Change to section 6. 6 - Instructions for use, handling and disposal
  • Change to section 7 - Marketing Authorisation Holder
  • Change to section 8 - MARKETING AUTHORISATION NUMBER(S)
  • Change to section 9 - Date of first Authorisation/renewal of the Authorisation
  • Change to section 10 date of revision of the text
  • Company name change or merger

Date of revision of text on the SPC: 01-Dec-2008

Legal Category:POM

Black Triangle (CHM): NO

Free-text change information supplied by the pharmaceutical company:



 

·         The company contact details have been changed from:

Syner-Med (Pharmaceuticals Products) Ltd
Beech House,
840 Brighton road,
Purley,
Surrey,
CR8 2BH
Telephone: +44 (0)845 634 2100
Fax: +44 (0)845 634 2101

to

Vifor Pharma UK Limited
The Old Stables
Bagshot Park
Bagshot
Surrey
GU19 5PJ
Telephone: +44 (0)1276 853600
Fax: +44 (0)1276 452341

 

·         The following sections have been amended to read as follows:

 

2.        QUALITATIVE AND QUANTITATIVE COMPOSITION

 

One millilitre of solution contains 20mg of iron as iron sucrose (iron (III)-hydroxide sucrose complex) 

 

Each 5 ml ampoule of Venofer contains 100 mg iron as iron sucrose (iron (III)-hydroxide sucrose complex) 

 

Each 5 ml vial of Venofer contains 100 mg iron as iron sucrose (iron (III)-hydroxide sucrose complex) 

 

For a full list of excipients, see 6.1. 

 

4.2.     Posology and Method of Administration 

 

Administration: Venofer must only be administered by the intravenous route. This may be by a slow intravenous injection or by an intravenous drip infusion.

 

Before administering the first dose to a new patient, a test dose of Venofer should be given. Venofer must not be used for intramuscular injection.

 

Adults and the elderly: The total cumulative dose of Venofer, equivalent to the total iron deficit (mg), is determined by the haemoglobin level and body weight. The dose for Venofer must be individually determined for each patient according to the total iron deficit calculated with the following formula: 

 

Total iron deficit [mg]      

=

body weight [kg] x (target Hb - actual Hb) [g/l] x 0.24* + depot iron [mg]

 

• Below 35 kg body weight: target Hb = 130 g/l and depot iron = 15 mg/kg body weight 

 

• 35 kg body weight and above: target Hb = 150 g/l and depot iron = 500 mg 

*Factor 0.24 = 0.0034 x 0.07 x 1000

(Iron content of haemoglobin 0.34%; Blood volume 7% of body weight; Factor 1000 = conversion from g to mg) 

 

The total amount of Venofer required is determined from either the above calculation or the following dosage table:

 

Body Weight[kg]

Total number of ampoules Venofer to be administered:

(1 ampoule of Venofer corresponds to 5ml)

Hb60g/l

Hb75g/l

Hb90g/l

Hb105g/l

30

9.5

8.5

7.5

6.5

35

12.5

11.5

10

9

40

13.5

12

11

9.5

45

15

13

11.5

10

50

16

14

12

10.5

55

17

15

13

11

60

18

16

13.5

11.5

65

19

16.5

14.5

12

70

20

17.5

15

12.5

75

21

18.5

16

13

80

22.5

19.5

16.5

13.5

85

23.5

20.5

17

14

90

24.5

21.5

18

14.5

To convert Hb(mM) to Hb(g/l), multiply the former by 16.1145.

 

 

Dosage: The total single dose must not exceed 200 mg of iron given not more than three times per week.If the total necessary dose exceeds the maximum allowed single dose,then the administration has to be split.

 

Children: The use of Venofer has not been adequately studied in children and, therefore, Venofer is not recommended for use in children.

 

Intravenous drip infusion: Venofer  must be diluted only in sterile 0.9% m/V sodium chloride solution: 

 

• 5 ml Venofer (100 mg iron) 

  in max. 100 ml sterile 0.9% m/V sodium chloride solution 

 

• 10 ml Venofer (200 mg iron) 

  in max. 200 ml sterile 0.9% m/V sodium chloride solution 

 

For stability reasons, dilutions to lower Venofer concentrations are not permissible.

 

Dilution must take place immediately prior to infusion and the solution should be administered as follows:

• 100 mg iron (5 ml Venofer) in at least 15 minutes

• 200 mg iron (10ml Venofer) in at least 30 minutes

 

The first 25 mg of iron (i.e. 25 ml of solution) should be infused as a test dose over a period of 15 minutes. If no adverse reactions occur during this time then the remaining portion of the infusion should be given at an infusion rate of not more than 50 ml in 15 minutes. 

 

Intravenous injection: Venofer  may be administered by slow intravenous injection at a rate of 1 ml undiluted solution per minute (i.e. 5 minutes per ampoule) and not exceeding  2 ampoules Venofer (200 mg iron) per injection.  Before administering a slow intravenous injection, a test dose of 1 ml (20 mg of iron) should be injected slowly over a period of 1 to 2 minutes. If no adverse events occur within 15 minutes of completing the test dose, then the remaining portion of the injection may be given.

 

Injection into dialyser: Venofer  may be administered during a haemodialysis session directly into the venous limb of the dialyser under the same procedures as those outlined for intravenous injection.

 

 

4.8.     Undesirable Effects 

 

The most frequently reported adverse drug reactions (ADRs) of Venofer  in clinical trials were transient taste perversion, hypotension, fever and shivering, injection site reactions and nausea, occurring in 0.5 to 1.5% of the patients. Non-serious anaphylactoid reactions occurred rarely. 

 

In general anaphylactoid reactions are potentially the most serious adverse reactions (see “Special warnings and Precautions for Use” section 4.4).

 

In clinical trials, the following adverse drug reactions have been reported in temporal relationship with the administration of Venofer, with at least a possible causal relationship: 

 

Nervous system disorders 

Common ( > 1/100, < 1/10): transient taste perversions (in particular metallic taste). 

Uncommon ( > 1/1000, < 1/100): headache; dizziness. 

Rare ( > 1/10000, < 1/1000): paraesthesia, syncope, loss of consciousness, burning sensation

 

Cardio-vascular disorders 

Uncommon ( > 1/1000, < 1/100): hypotension and collapse; tachycardia and palpitations. 

Rare ( > 1/10000, < 1/1000): hypertension.

 

Respiratory, thoracic and mediastinal disorders 

Uncommon ( > 1/1000, < 1/100): bronchospasm, dyspnoea.

 

Gastrointestinal disorders 

Uncommon ( > 1/1000, < 1/100): nausea; vomiting; abdominal pain; diarrhoea. 

 

Skin and subcutaneous tissue disorders 

Uncommon (> 1/1000, < 1/100): pruritus; urticaria; rash, exanthema, erythema. 

 

Musculoskeletal, connective tissue and bone disorders 

Uncommon (> 1/1000, < 1/100): muscle cramps, myalgia. 

 

General disorders and administration site disorders 

Uncommon ( > 1/1000, < 1/100): fever, shivering, flushing; chest pain and tightness. Injection site disorders such as superficial phlebitis, burning, swelling. 

Rare ( > 1/10000, < 1/1000): arthralgia, peripheral oedema; fatigue, asthenia; malaise, feeling hot, oedema.

 

Immune system disorders 

Rare ( > 1/10000, < 1/1000): anaphylactoid reactions

 

Moreover, in spontaneous reports the following adverse reactions have been reported: 

Isolated cases: reduced level of consciousness, light-headed feeling, confusion, angio-oedema; swelling of joints, hyperhidrosis, back pain, bradycardia, chromaturia

 

6.5.     Nature and Contents of Container 

 

5 ml solution in one ampoule (type I glass) in pack sizes of 5. 

5 ml solution in one vial (type I glass) in pack sizes of 5. 

 

6.6.     Special precautions for disposal and other handling

 

Ampoules or vials should be visually inspected for sediment and damage before use. 

Only those with sediment free and homogenous solution must be used. 

The diluted solution must appear as brown and clear. 

See also 6.3 shelf-life. 

Each ampoule or vial of Venofer is intended for single use only. Discard any remaining contents after first use.

 

                Please note the following key changes made to section 4.8 (Undesirable effects).

 

·         Under subheading Nervous System Disorders; syncope, loss of consciousness and burning sensation have been added as rare (>1/10000, <1/1000) undesirable effects.

 

·         Under subheading Cardio-Vascular Disorders; hypertension has been added as a rare (>1/10000, <1/1000) undesirable effect.

 

·         Under subheading General Disorders and Administration Site Disorders; anaphylactoid reactions has been removed and the undesirable effects of feeling hot and oedema have been added as rare (>1/10000, <1/1000)

 

·         A further subheading has been added to section 4.8 titled Immune System Disorders. Listing anaphylactoid reactions as rare (>1/10000, <1/1000) undesirable effect.

 

·         The contact details in section 7 (Marketing Authoristation Holder) has been updated from:

 

Vifor France Sa

123, rue Jules Guesde

92300 Levallois-Perret

France

 

To

 

Vifor France SA

7-13, Bd Paul Emile Victor

92200 Neuilly sur-Seine

France

Tel. +33 (0) 1 41 06 58 90

Fax. +33 (0)1 41 06 58 99

Email: contact@vifor-france.fr 

 

·    The Ireland Marketing Authorisation Number PA 949/1/1 and date of first authorization/renewal of the authorization 20.03.2000 / 08.06.2003 have been removed from sections 8 (MARKETING AUTHORISATION NUMBER(S)) and 9 (DATE OF FIRST AUTHORISATION / RENEWAL OF AUTHORISATION) , respectively.

 

·         The date of revision of text has been updated from August 2006 to 01.12.2008

 

 

 

 

 

 

 

 

 

 

Company contact details

Vifor Pharma UK Limited

Company image
Address

The Old Stables, Bagshot Park, Surrey, GU19 5PJ, UK

Fax

+44 (0)1276 452 341

Medical Information e-mail
Medical Information Fax

+44 (0)1276 452 341

Telephone

+44 (0)1276 853 600

Medical Information Direct Line

+44 (0)1276 853 633

Customer Care direct line

+44 (0)1276 853 633

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?

Active ingredients

iron sucrose

Legal categories

POM - Prescription Only Medicine

This site uses cookies. By continuing to browse the site you are agreeing to our policy on the use of cookies. Continue